IDEXX Laboratories revenue and financials
$515.41Change from previous close: −2.21%Absolute change: −$11.66
In the fiscal year ended December 2025, IDEXX Laboratories reported revenue of $4.3B (+10.42% year over year). Net income was $1.06B, a net margin of 24.6%.
Fiscal year ending in December. Sources and method on the page Methodology and sources.
At a glance
- Revenue growth
- +10.42%
- 2025 vs 2024
- Net income growth
- +19.33%
- 2025 vs 2024
- Net margin
- 24.6%
- 2024: 22.8%
Financial data
Amounts in millions of USD; per-share values in USD; shares in millions.
| Item | Q2 2026 | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | Q2 2024 | Q1 2024 | Q4 2023 | Q3 2023 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Operating cash flow | 347 | 266 | 356 | 402 | 186 | 238 | 262 | 220 | 248 | 199 | 250 | 272 |
| Depreciation and amortization | 41.1 | 37.7 | 38.7 | 36.6 | 35.8 | 34.1 | 33.7 | 34.1 | 32.2 | 29.9 | 29.7 | 29.0 |
| Capital expenditure | -24.6 | -32.0 | -29.4 | -31.1 | -34.1 | -30.0 | -29.3 | -28.1 | -33.3 | -30.3 | -32.6 | -34.1 |
| Investing cash flow | -25.5 | -33.5 | -28.1 | -44.9 | -33.6 | -29.6 | -39.8 | -27.4 | -32.9 | -107 | -30.4 | -27.8 |
| Financing cash flow | -325 | -211 | -356 | -313 | -166 | -330 | -233 | -291 | -210 | -144 | -102 | -43.0 |
| Share repurchases | -347 | -362 | -238 | -240 | -339 | -407 | -246 | -221 | -216 | -165 | -36.9 | -35.3 |
| Debt issued | -11.0 | 132 | 193 | -124 | 260 | 69.5 | — | — | — | — | — | — |
| Debt repaid | — | — | -325 | 0.0 | -103 | — | — | -75.0 | — | — | -75.0 | -12.2 |
| Effect of exchange rates | -0.1 | -0.8 | -0.0 | -0.6 | 14.1 | -2.3 | -9.8 | 5.3 | -1.0 | -4.1 | 4.7 | -2.7 |
| Net change in cash | -3.6 | 20.5 | -28.1 | 43.6 | 0.6 | -124 | -20.4 | -93.0 | 4.2 | -56.5 | 122 | 199 |
| Free cash flow | 323 | 234 | 326 | 371 | 152 | 208 | 233 | 192 | 215 | 168 | 217 | 238 |
| Levered free cash flow | 230 | 166 | 286 | 227 | 119 | 159 | 171 | 172 | 254 | 139 | 228 | 196 |